Bright light and a walk: a new prescription for cancer sleep troubles?
NCT ID NCT05875870
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests a six-week program of morning bright light exposure combined with moderate walking for people with lung or esophageal cancer. The goal is to see if it can improve sleep-wake rhythms, reduce physical and emotional symptoms, and boost quality of life. Two hundred participants will be tracked using activity monitors and sleep questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- bright light exposure and walking
- What this could lead to
- If it works, this could offer a simple, drug-free way to improve sleep, mood, and daily function for people with thoracic cancer.
- What could go wrong
- This is a small, early-stage study with no control group, so results may not be definitive. The program requires daily commitment, which may be hard for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Medical University Hospital
RECRUITINGTaipei, 110, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei City, Taipei, 112, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Your Tumor's DNA might predict immunotherapy success